mHTT has been shown to interfere with the binding of the CREB/TAF4 complex on PGC-1α promoter, repressing its expression, and evidence suggest that reduced PGC-1α level/activity might contribute to neurotoxicity in HD (Cui et al., 2006; Weydt et al., 2006). Here, CREB1 is linked to Huntington disease.